The National Institute for Health and Clinical Excellent declined to recommend two expensive cancer drugs from Novartis and another from Bristol-Myers Squibb from being used within the state-run health service,Reuters writes.
NICE rebuffed Afinitor as a second-line treatment for kidney cancer, adding there was limited data about how long it could extend life. And the agency declined to recommend Tasigna and Bristol's Sprycel for chronic myeloid leukaemia in patients who are intolerant to Gleevec - an older drug from Novartis - because effectiveness evidence was "very poor" and their cost was "extremely high".
"It would be heartening to hear that the pharmaceutical company manufacturers are prepared to share some of the very high cost of the drugs with the NHS (National Health Service)," NICE director Peter Littlejohns says in a statement. NICE has struck several previous deals with companies to reduce the cost of medicines before recommending them for use in the NHS.